Valeant makes Canadian acquisition to boost derma reach
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals has agreed to acquire Laboratoire Dr Renaud, a Canadian cosmeceutical company, for around Can$23 million (US$22 million). As part of the transaction Valeant will acquire a lease for a 45,000 square foot manufacturing facility specialising in topical formulations.